Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
September 03, 2024 07:00 ET
|
Amphista Therapeutics
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer
September 03, 2024 03:00 ET
|
Amphista Therapeutics
Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer The appointment will accelerate the Company’s next phase of growth, advancing its next generation Targeted Glue™ protein...
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium
May 23, 2024 07:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Protein Degradation in Focus Symposium First presentation of a novel mechanism of...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
January 24, 2024 07:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders
January 24, 2024 03:00 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein degraders First...
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
September 26, 2023 09:30 ET
|
Amphista Therapeutics
PRESS RELEASE Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company” or...